Literature DB >> 9412558

Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study.

L Burdet1, B de Muralt, Y Schutz, C Pichard, J W Fitting.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often develop weight loss, which is associated with increased mortality. Recombinant human growth hormone (rhGH) treatment has been proposed to improve nitrogen balance and to increase muscle strength in these patients. The aim of this study was to assess the effects of rhGH administration on the nutritional status, resting metabolism, muscle strength, exercise tolerance, dyspnea, and subjective well-being of underweight patients with stable COPD. Sixteen patients attending a pulmonary rehabilitation program (age: 66 +/- 9 yr; weight: 77 +/- 7% of ideal body weight; FEV1: 39 +/- 13% of predicted) were randomly treated daily with either 0.15 IU/kg rhGH or placebo during 3 wk in a double-blind fashion. Measurements were made at the beginning (DO) and at the end (D21) of treatment and 2 mo later (D81). Body weight was similar in the two groups during the study, but lean body mass was significantly higher in the rhGH group at D21 (p < 0.01) and D81 (p < 0.05). The increase in lean body mass was 2.3 +/- 1.6 kg in the rhGH group and 1.1 +/- 0.9 kg in the control group at D21 and 1.9 +/- 1.6 kg in the rhGH group and 0.7 +/- 2.1 kg in the control group at D81. At D21, the resting energy expenditure was increased in the rhGH group (107.8% of DO, p < 0.001 compared with the control group). At D21 and D81, the changes in maximal respiratory pressures, handgrip strength, maximal exercise capacity, and subjective well-being were similar in the two groups. At D21, the 6-min walking distance decreased in the rhGH group (-13 +/- 31%) and increased in the control group (+10 +/- 14%; p < 0.01). We conclude that the daily administration of 0.15 IU/kg rhGH during 3 wk increases lean body mass but does not improve muscle strength or exercise tolerance in underweight patients with COPD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9412558     DOI: 10.1164/ajrccm.156.6.9704142

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

Review 1.  Enhancing physical performance in chronic obstructive pulmonary disease.

Authors:  M C Steiner; M D Morgan
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

Review 2.  Selecting lung transplant candidates: where do current guidelines fall short?

Authors:  Jaime L Hook; David J Lederer
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

3.  Ghrelin administration for chronic respiratory failure: a randomized dose-comparison trial.

Authors:  Nobuhiro Matsumoto; Keisuke Miki; Hironobu Tsubouchi; Akihiro Sakamoto; Yasuji Arimura; Shigehisa Yanagi; Hirotoshi Iiboshi; Makoto Yoshida; Ryosuke Souma; Hiroshi Ishimoto; Yoshifumi Yamamoto; Kazuhiro Yatera; Masanori Yoshikawa; Hironori Sagara; Tomoaki Iwanaga; Hiroshi Mukae; Ryoji Maekura; Hiroshi Kimura; Masamitsu Nakazato; Kenji Kangawa
Journal:  Lung       Date:  2015-01-30       Impact factor: 2.584

4.  Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease.

Authors:  J P Fuld; L P Kilduff; J A Neder; Y Pitsiladis; M E J Lean; S A Ward; M M Cotton
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

Review 5.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

6.  Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

Authors:  Michael I Polkey; Jens Praestgaard; Amy Berwick; Frits M E Franssen; Dave Singh; Michael C Steiner; Richard Casaburi; Hanns-Christian Tillmann; Estelle Lach-Trifilieff; Ronenn Roubenoff; Daniel S Rooks
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

Review 7.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 8.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

9.  Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis.

Authors:  A Schibler; R von der Heiden; P Birrer; P E Mullis
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

Review 10.  Reversal of chronic obstructive pulmonary disease-associated weight loss : are there pharmacological treatment options?

Authors:  Jean K Berry; Charles Baum
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.